STEPHANIE MCKAY: Open Payments
NPI 1710603865 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,337 in 61 payments from 17 companies in 2025. Trend: 2023 $2,144 · 2024 $2,653 · 2025 $1,337
Food & beverage: $1,337
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $192 |
| Neurocrine BioSciences, Inc. | 7 | $153 |
| Otsuka America Pharmaceutical, Inc. | 7 | $142 |
| Axsome Therapeutics, Inc. | 10 | $135 |
| Lundbeck LLC | 4 | $108 |
| Janssen Pharmaceuticals, Inc | 4 | $94 |
| Alkermes, Inc. | 3 | $87 |
| E.R. Squibb & Sons, L.L.C. | 3 | $86 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Tris Pharma Inc | 3 | $51 |
Products named: REXULTI, CAPLYTA, INGREZZA, Auvelity, COBENFY, LYBALVI, INVEGA SUSTENNA, Dyanavel XR.
Industry payments across DE — which companies pay providers there.
